Who makes U.S.-approved Neupogen®?

U.S.-approved Neupogen® is developed by Pfizer.

What development phase is U.S.-approved Neupogen® in?

U.S.-approved Neupogen® is in Phase 1.

Last reviewed 2026-04-19 · How we verify

U.S.-approved Neupogen®

Pfizer · Phase 1 active Biologic

At a glance

Generic name	U.S.-approved Neupogen®
Sponsor	Pfizer
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen) (PHASE1)
A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

U.S.-approved Neupogen® CI brief — competitive landscape report
U.S.-approved Neupogen® updates RSS · CI watch RSS
Pfizer portfolio CI